Eric N Taylor1, Andrew N Hoofnagle2, Gary C Curhan3. 1. Channing Division of Network Medicine and Division of Nephrology and Transplantation, Maine Medical Center, Portland, Maine; entaylor@partners.org. 2. Departments of Medicine and Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington; and. 3. Channing Division of Network Medicine and Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Calcium and phosphorus regulatory hormones may contribute to the pathogenesis of calcium nephrolithiasis. However, there has been no prospective study to date of plasma hormone levels and risk of kidney stones. This study aimed to examine independent associations between plasma levels of 1,25-dihydroxyvitamin D (1,25[OH]2D), 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, fibroblast growth factor 23 (FGF23), parathyroid hormone, calcium, phosphate, and creatinine and the subsequent risk of incident kidney stones. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study was a prospective, nested case-control study of men in the Health Professionals Follow-Up Study who were free of diagnosed nephrolithiasis at blood draw. During 12 years of follow-up, 356 men developed an incident symptomatic kidney stone. Using risk set sampling, controls were selected in a 2:1 ratio (n=712 controls) and matched for age, race, and year, month, and time of day of blood collection. RESULTS: Baseline plasma levels of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, parathyroid hormone, calcium, phosphate, and creatinine were similar in cases and controls. Mean 1,25(OH)2D and median FGF23 levels were higher in cases than controls but differences were small and statistically nonsignificant (45.7 versus 44.2 pg/ml, P=0.07 for 1,25[OH]2D; 47.6 versus 45.1 pg/ml, P=0.08 for FGF23). However, after adjusting for body mass index, diet, plasma factors, and other covariates, the odds ratios of incident symptomatic kidney stones in the highest compared with lowest quartiles were 1.73 (95% confidence interval, 1.11 to 2.71; P for trend 0.01) for 1,25(OH)2D and 1.45 (95% confidence interval, 0.96 to 2.19; P for trend 0.03) for FGF23. There were no significant associations between other plasma factors and kidney stone risk. CONCLUSIONS: Higher plasma 1,25(OH)2D, even in ranges considered normal, is independently associated with higher risk of symptomatic kidney stones. Although of borderline statistical significance, these findings also suggest that higher FGF23 may be associated with risk.
BACKGROUND AND OBJECTIVES:Calcium and phosphorus regulatory hormones may contribute to the pathogenesis of calciumnephrolithiasis. However, there has been no prospective study to date of plasma hormone levels and risk of kidney stones. This study aimed to examine independent associations between plasma levels of 1,25-dihydroxyvitamin D (1,25[OH]2D), 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, fibroblast growth factor 23 (FGF23), parathyroid hormone, calcium, phosphate, and creatinine and the subsequent risk of incident kidney stones. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study was a prospective, nested case-control study of men in the Health Professionals Follow-Up Study who were free of diagnosed nephrolithiasis at blood draw. During 12 years of follow-up, 356 men developed an incident symptomatic kidney stone. Using risk set sampling, controls were selected in a 2:1 ratio (n=712 controls) and matched for age, race, and year, month, and time of day of blood collection. RESULTS: Baseline plasma levels of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, parathyroid hormone, calcium, phosphate, and creatinine were similar in cases and controls. Mean 1,25(OH)2D and median FGF23 levels were higher in cases than controls but differences were small and statistically nonsignificant (45.7 versus 44.2 pg/ml, P=0.07 for 1,25[OH]2D; 47.6 versus 45.1 pg/ml, P=0.08 for FGF23). However, after adjusting for body mass index, diet, plasma factors, and other covariates, the odds ratios of incident symptomatic kidney stones in the highest compared with lowest quartiles were 1.73 (95% confidence interval, 1.11 to 2.71; P for trend 0.01) for 1,25(OH)2D and 1.45 (95% confidence interval, 0.96 to 2.19; P for trend 0.03) for FGF23. There were no significant associations between other plasma factors and kidney stone risk. CONCLUSIONS: Higher plasma 1,25(OH)2D, even in ranges considered normal, is independently associated with higher risk of symptomatic kidney stones. Although of borderline statistical significance, these findings also suggest that higher FGF23 may be associated with risk.
Authors: David E Leaf; Ruslan Korets; Eric N Taylor; Jie Tang; John R Asplin; David S Goldfarb; Mantu Gupta; Gary C Curhan Journal: Clin J Am Soc Nephrol Date: 2012-03-15 Impact factor: 8.237
Authors: Galina Nesterova; May Christine Malicdan; Kaori Yasuda; Toshiyuki Sakaki; Thierry Vilboux; Carla Ciccone; Ronald Horst; Yan Huang; Gretchen Golas; Wendy Introne; Marjan Huizing; David Adams; Cornelius F Boerkoel; Michael T Collins; William A Gahl Journal: Clin J Am Soc Nephrol Date: 2013-01-04 Impact factor: 8.237
Authors: Nancy E Lane; Neeta Parimi; Maripat Corr; Wei Yao; Jane A Cauley; Carrie M Nielson; Joseph H Ix; Deborah Kado; Eric Orwoll Journal: J Bone Miner Res Date: 2013-11 Impact factor: 6.741
Authors: Anna Jovanovich; Petra Bùzková; Michel Chonchol; John Robbins; Howard A Fink; Ian H de Boer; Bryan Kestenbaum; Ronit Katz; Laura Carbone; Jennifer Lee; Gail A Laughlin; Kenneth J Mukamal; Linda F Fried; Michael G Shlipak; Joachim H Ix Journal: J Clin Endocrinol Metab Date: 2013-06-14 Impact factor: 5.958
Authors: Charles D Scales; Gregory E Tasian; Andrew L Schwaderer; David S Goldfarb; Robert A Star; Ziya Kirkali Journal: Clin J Am Soc Nephrol Date: 2016-03-10 Impact factor: 8.237
Authors: Hemamalini Ketha; Ravinder J Singh; Stefan K Grebe; Eric J Bergstralh; Andrew D Rule; John C Lieske; Rajiv Kumar Journal: PLoS One Date: 2015-09-02 Impact factor: 3.240
Authors: Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares; Uri Saggie Alon Journal: Biomed Res Int Date: 2017-12-31 Impact factor: 3.411